The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

CTK2G4683     prop-1-yn-1-amine

Synonyms: LS-125795, NSC 80642, AKOS006350300, BRN 0773681, AC1L29EB, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of Propargylamine

 

Psychiatry related information on Propargylamine

 

High impact information on Propargylamine

 

Chemical compound and disease context of Propargylamine

 

Biological context of Propargylamine

 

Anatomical context of Propargylamine

 

Associations of Propargylamine with other chemical compounds

  • It is here proposed that L-deprenyl, being a propargylamine, at physiological pH has a protonated amino group able to interact with critical aromatic or anionic amino acidic residues [17].
 

Gene context of Propargylamine

  • The anti-apoptotic activity of these propargylamine-containing derivatives may be related to their ability to delay the opening of voltage-dependent anion channels (VDAC), which are part of the mitochondrial permeability transition pore [16].
  • Some of these alkyl propargylamine MAO-B inhibitors, which do not possess the amphetamine-like moiety of L-deprenyl, may have significant neuropsychopharmacological implications [18].
  • Their neuroprotective effect has been demonstrated to be associated directly with the propargylamine moiety, which protects mitochondrial viability and MTPp by activating Bcl-2 and protein kinase C (PKC) and by downregulating the proapoptotic FAS and Bax protein families [19].
  • Interestingly, we have recently shown that another propargylamine, rasagiline not only increases antioxidant enzyme activities (CAT and SOD) in brain dopaminergic regions as (-)deprenyl does, but also increases CAT and SOD activities in extrabrain catecholaminergic systems such as the heart and kidneys as well [20].
  • The neuroprotective activity of propargylamines led us to develop several novel bifunctional iron chelator from our prototype brain permeable iron chelators, VK-28, possessing propargylamine moiety (HLA-20, M30 and M30A) to iron out iron from the brain [21].
 

Analytical, diagnostic and therapeutic context of Propargylamine

References

  1. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Mandel, S., Weinreb, O., Amit, T., Youdim, M.B. Brain Res. Brain Res. Rev. (2005) [Pubmed]
  2. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. Chen, J.J., Swope, D.M. Journal of clinical pharmacology. (2005) [Pubmed]
  3. Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. Bar-Am, O., Weinreb, O., Amit, T., Youdim, M.B. FASEB J. (2005) [Pubmed]
  4. Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil. Youdim, M.B., Amit, T., Bar-Am, O., Weinreb, O., Yogev-Falach, M. Neurotoxicity research (2006) [Pubmed]
  5. Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease? Tabakman, R., Lecht, S., Lazarovici, P. Bioessays (2004) [Pubmed]
  6. A Mechanism-Based Inactivator for Histone Demethylase LSD1. Culhane, J.C., Szewczuk, L.M., Liu, X., Da, G., Marmorstein, R., Cole, P.A. J. Am. Chem. Soc. (2006) [Pubmed]
  7. Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease. Avramovich-Tirosh, Y., Amit, T., Bar-Am, O., Zheng, H., Fridkin, M., Youdim, M.B. J. Neurochem. (2007) [Pubmed]
  8. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. Sterling, J., Herzig, Y., Goren, T., Finkelstein, N., Lerner, D., Goldenberg, W., Miskolczi, I., Molnar, S., Rantal, F., Tamas, T., Toth, G., Zagyva, A., Zekany, A., Finberg, J., Lavian, G., Gross, A., Friedman, R., Razin, M., Huang, W., Krais, B., Chorev, M., Youdim, M.B., Weinstock, M. J. Med. Chem. (2002) [Pubmed]
  9. Neurochemical and neuroprotective effects of some aliphatic propargylamines: new selective nonamphetamine-like monoamine oxidase B inhibitors. Yu, P.H., Davis, B.A., Durden, D.A., Barber, A., Terleckyj, I., Nicklas, W.G., Boulton, A.A. J. Neurochem. (1994) [Pubmed]
  10. The neuroprotective effects of CGP 3466B in the best in vivo model of Parkinson's disease, the bilaterally MPTP-treated rhesus monkey. Andringa, G., Cools, A.R. J. Neural Transm. Suppl. (2000) [Pubmed]
  11. The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline. Youdim, M.B., Amit, T., Falach-Yogev, M., Am, O.B., Maruyama, W., Naoi, M. Biochem. Pharmacol. (2003) [Pubmed]
  12. Sequential amination/annulation/aromatization reaction of carbonyl compounds and propargylamine: a new one-pot approach to functionalized pyridines. Abbiati, G., Arcadi, A., Bianchi, G., Di Giuseppe, S., Marinelli, F., Rossi, E. J. Org. Chem. (2003) [Pubmed]
  13. CGP 3466B has no effect on disease course of (G93A) mSOD1 transgenic mice. Groeneveld, G.J., van Muiswinkel, F.L., de Leeuw van Weenen, J., Blauw, H., Veldink, J.H., Wokke, J.H., van den Berg, L.H., Bär, P.R. Amyotroph. Lateral Scler. Other Motor Neuron Disord. (2004) [Pubmed]
  14. Relationship between the hydrophobic physicochemical parameters and biological activity of some monoamine oxidase inhibitory drugs. Forgács, E., Magyar, K. Biochem. Mol. Biol. Int. (1994) [Pubmed]
  15. Inhibition by aminoacetonitrile and propargylamine of glycine cleavage system from rat brain and liver mitochondria. Benavides, J., Croci, N., Strolin Benedetti, M. Biochem. Pharmacol. (1983) [Pubmed]
  16. Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. Youdim, M.B., Weinstock, M. Cell. Mol. Neurobiol. (2001) [Pubmed]
  17. L-Deprenyl as an inhibitor of menadione-induced permeability transition in liver mitochondria. De Marchi, U., Pietrangeli, P., Marcocci, L., Mondovì, B., Toninello, A. Biochem. Pharmacol. (2003) [Pubmed]
  18. Effect of structural modification of alkyl N-propargylamines on the selective inhibition of monoamine oxidase B activity. Yu, P.H., Davis, B.A., Boulton, A.A. Biochem. Pharmacol. (1993) [Pubmed]
  19. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. Youdim, M.B., Bar Am, O., Yogev-Falach, M., Weinreb, O., Maruyama, W., Naoi, M., Amit, T. J. Neurosci. Res. (2005) [Pubmed]
  20. Do antioxidant strategies work against aging and age-associated disorders? Propargylamines: a possible antioxidant strategy. Kitani, K., Minami, C., Yamamoto, T., Maruyama, W., Kanai, S., Ivy, G.O., Carrillo, M.C. Ann. N. Y. Acad. Sci. (2001) [Pubmed]
  21. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. Youdim, M.B., Fridkin, M., Zheng, H. Mech. Ageing Dev. (2005) [Pubmed]
  22. Interaction of monoamine oxidase inhibitory drugs with some phospholipids. Szögyi, M., Cserháti, T. Journal of pharmaceutical and biomedical analysis. (1993) [Pubmed]
 
WikiGenes - Universities